Pentixapharm Holding AG Reports 2024 Financial Results and 2025 Outlook

Berlin, April 15, 2025 – Pentixapharm Holding AG has announced its financial results for the year 2024, revealing a net loss of EUR 12.8 million. The biotech company forecasts a further net loss of approximately EUR 23.5 million for the upcoming 2025 financial year. These projections reflect anticipated research and development expenditures of about EUR 11 million, along with personnel and operational costs estimated at EUR 9.5 million. Notably, potential revenues from out-licensing activities have not been factored into these forecasts.

The company also released its full Annual Report for 2024 and plans to hold an investor call at 2:00 p.m. CEST to discuss these financial outcomes in detail. Pentixapharm continues to focus on developing radiopharmaceuticals, specializing in targeted radiopharmaceutical approaches with promising diagnostic and therapeutic applications. The firm operates in Berlin and Würzburg, Germany, and is renowned for innovative ligand-based compounds targeting various diseases.